Tivozanib Confirmed Superior to Sorafenib For Treatment of Refractory Metastatic RCC
May 29th 2020"We believe the TIVO-3 data demonstrate a favorable risk/benefit profile for tivozanib in the growing population of patients who have relapsed or become refractory to multiple lines of therapy, including checkpoint inhibitors."
Read More
Co-Inhibition of TIGIT and PD-L1 Generates Promising Efficacy in NSCLC
May 29th 2020Frontline treatment with the TIGIT inhibitor tiragolumab plus atezolizumab demonstrated greater efficacy versus single-agent checkpoint inhibitor therapy in locally advanced or metastatic non–small cell lung cancer, according to results of the phase 2 CITYSCAPE trial reported at the 2020 American Society of Clinical Oncology Virtual Scientific Program.
Read More
Encouraging Preliminary Findings Demonstrated for Belantamab Mafodotin Combo in R/R Multiple Myeloma
May 29th 2020“Preliminary data for the 18 patients who have received belantamab mafodotin 2.5 mg/kg single dosing with bortezomib/dexamethasone suggests that this combination has an acceptable safety profile with no new safety signals identified. Clinical response looks promising."
Read More
Improved Responses Achieved for R/R Multiple Myeloma With Selinexor Combo
May 29th 2020Selinexor in combination with bortezomib and dexamethasone resulted in improvements in responses and outcomes compared with bortezomib and dexamethasone alone in patients with relapsed or refractory multiple myeloma, according to findings from the phase 3 BOSTON trial from the 2020 ASCO Virtual Scientific Program.
Read More
PFS Data Show Carfilzomib Triplet Remains Inferior to VRd in Newly Diagnosed Myeloma
May 29th 2020Given the higher efficacy of carfilzomib seen in recent phase 2 trials, investigators sought to determine if carfilzomib could replace bortezomib in the current standard of care triplet induction regimen in standard and intermediate risk NDMM, but the study failed.
Read More
Overall Survival Not Increased With Locoregional Therapy in Advanced Breast Cancer
May 28th 2020"Based on the results of our study, women who present with a new diagnosis of breast cancer already in stage IV should not be offered surgery and radiation for the primary breast tumor with the expectation of a survival benefit."
Read More
Adjuvant Osimertinib Leads to Significant Boost in DFS in Early-Stage EGFR+ NSCLC
May 28th 2020"Adjuvant osimertinib is the first targeted agent in a global randomized trial to show a statistically significant and clinically meaningful improvement in disease-free survival in patients with stage IB/II/IIIA EGFR mutation–positive non–small cell lung cancer."
Read More
Pembrolizumab Extends PFS in Newly Diagnosed MSI-H/dMMR mCRC
May 28th 2020"Pembrolizumab works in non-randomized studies in this group of patients with advanced disease. This randomized study demonstrates a huge benefit in the first-line [setting] with pembrolizumab and should be the new standard of care."
Read More
Maintenance Olaparib Provides Significant Long-Term OS Benefit in Relapsed Ovarian Cancer
May 13th 2020“In the final SOLO2 analysis, maintenance olaparib provided a clinically meaningful improvement of 12.9 months [in] median overall survival. These results demonstrate that olaparib maintenance monotherapy not only delays disease progression but also improves overall survival in women with platinum-sensitive ovarian cancer and a BRCA mutation.”
Read More
Analyses Demonstrate Efficacy of Larotrectinib in TRK+ Adult and Pediatric Patient Populations
June 12th 2019Larotrectinib demonstrated efficacy across analyses for both pediatric patients and those with brain metastases or primary central nervous system tumors, whether pediatric or adult, with TRK fusions.
Read More
RFS Increased With Neoadjuvant T-VEC Therapy in Advanced Melanoma
June 7th 2019Neoadjuvant talimogene laherparepvec (T-VEC) led to a significant improvement in the 1-year recurrence-free survival rate in patients with resectable advanced melanoma compared with surgery alone, according to a randomized trial presented at the 2019 ASCO Annual Meeting.
Read More
Phase III NALA Trial Results in Higher PFS With Neratinib Combo for HER2+ Breast Cancer
June 6th 2019Combining neratinib with capecitabine showed a 24% reduction in the risk of disease progression or death compared with lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer who had previously received 2 lines of HER2-targeted therapy, according to the results of the phase III NALA trial presented at the 2019 ASCO Annual Meeting.
Read More
PFS Rate in ER+ Breast Cancer Doubled With Capivasertib Plus Fulvestrant
June 5th 2019In the placebo-controlled phase II FAKTION trial, a combination of capivasertib and fulvestrant showed a significant increase in progression-free survival compared to the use of fulvestrant alone in patients with endocrine-resistant estrogen receptor-positive advanced breast cancer.
Read More
Newer PD-1 Inhibitor Active With Dabrafenib and Trametinib in BRAF V600+ Melanoma
June 5th 2019The investigational PD-1 inhibitor spartalizumab demonstrated a high rate of complete responses in combination with dabrafenib and trametinib in patients with previously untreated advanced <em>BRAF </em>V600–mutant melanoma. Patients pooled from 2 parts of the 3-part COMBI-i study demonstrated a CR rate of more than 40%.
Read More
PFS Prolonged With Olaparib in Patients With BRCA+ Ovarian Cancer
June 5th 2019Compared to chemotherapy, treatment with the PARP inhibitor olaparib reduced the risk of disease progression or death by 38% in patients with platinum-sensitive, relapsed, germline <em>BRCA1/2</em>-mutated ovarian cancer who had received at least 2 prior chemotherapy regimens, based on topline findings from the confirmatory phase III SOLO3 trial.
Read More
Venetoclax/Obinutuzumab Combo Advances PFS in Previously Untreated CLL
June 5th 2019According to the pivotal phase III CLL14 study presented during the 2019 American Society of Clinical Oncology Annual Meeting, venetoclax plus obinutuzumab demonstrated a lengthening in progression-free survival time for patients with previously untreated chronic lymphocytic leukemia compared with obinutuzumab plus chlorambucil. Trial results show that the chemotherapy-free combination reduced the risk for disease worsening or death by 65% compared with obinutuzumab plus chlorambucil.
Read More
Overall Survival Update From COLUMBUS Trial in BRAF V600-Mutant Melanoma
June 4th 2019Keith T. Flaherty, MD, director, Termeer Center for Targeted Therapy, Massachusetts General Hospital Cancer Center, professor of medicine, Harvard Medical School, shares updated overall survival data from the phase III COLUMBUS trial examining encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF V600-mutant melanoma.
Read More
Chemo-Free Doublet Significantly Improved PFS in Recurrent Ovarian Cancer
June 4th 2019The combination of niraparib and bevacizumab demonstrated a significant increase in progression-free survival compared with niraparib alone in patients with platinum-sensitive recurrent ovarian cancer, according to the results of the randomized ENGOT-OV24 trial.<br />
Read More
Two New Targeted Therapies Appear Encouraging for Difficult Drivers in NSCLC
June 4th 2019Two targeted therapies in development have demonstrated encouraging activity as potential treatments targeting hard-to-target driver alterations in lung cancer. During the 2019 ASCO Annual Meeting, Christine M. Lovly, MD, PhD, reviewed the early promising findings for TAK-788 for patients with non–small cell lung cancer harboring <em>EGFR</em> exon 20 insertions and for BLU-667 for patients with <em>RET </em>rearrangements.
Read More
First-in-Class Inhibitor Induces Responses in KRAS G12C+ NSCLC
June 4th 2019Half of patients with <em>KRAS</em> G12C–positive advanced non–small cell lung cancer achieved a response from treatment with the investigational KRAS G12C inhibitor, AMG 510, in a phase I study presented at the 2019 ASCO Annual Meeting.
Read More
Results of Niraparib/Bevacizumab Combo in Platinum-Sensitive Recurrent Ovarian Cancer
June 4th 2019Mansoor Mirza, MD, chief oncologist, Department of Oncology, Copenhagen University Hospital, discusses the findings from NSGO-AVANOVA2/ENGOT-OV24, the randomized controlled chemotherapy-free study of niraparib (Zejula) and bevacizumab (Avastin) versus niraparib alone in recurrent platinum-sensitive ovarian cancer.
Read More
Frontline Ramucirumab Combo Delays Progression in EGFR+ NSCLC
June 4th 2019When the targeted agents ramucirumab and erlotinib were combined, progression was delayed by 7 months in patients with newly diagnosed <em>EGFR</em>-positive non–small cell lung cancer compared to erlotinib alone, according to findings from the phase III RELAY trial.
Read More
Two MET Inhibitors Demonstrate Clinical Activity in METex14+ NSCLC
June 4th 2019Promising responses have been seen with 2 highly selective, investigational MET inhibitors—tepotinib and capmatinib—in both the first- and second-line setting for patients with <em>MET</em> exon 14–altered advanced non–small cell lung cancer.
Read More